Tirzepatide
Dual-action appetite and metabolic support
About Tirzepatide
Tirzepatide is the first dual-receptor agonist approved for chronic weight management and type 2 diabetes. It activates both GLP-1 and GIP receptors — two of the body's natural metabolic hormones — to reduce appetite, slow gastric emptying, and improve how your body uses insulin. Most patients take it as a once-weekly subcutaneous injection that is gradually titrated up. In head-to-head studies, tirzepatide has produced greater average weight loss than single-agonist GLP-1 therapies.
Common reasons patients ask about tirzepatide:
- Strong appetite reduction and lower cravings
- Greater average weight loss than single-agonist GLP-1 therapies in head-to-head data
- Improved blood sugar control and insulin sensitivity
- Less mealtime preoccupation — easier to make smaller meals satisfying
Data
What the studies show
Tirzepatide has been studied extensively in the SURMOUNT program (weight management) and the SURPASS program (type 2 diabetes). Results have consistently shown substantial weight loss and improved glycemic control, with the highest doses producing the largest average reductions.
~22.5%
Average body weight reduction at 72 weeks on tirzepatide 15 mg in SURMOUNT-1
~2.1%
A1C reduction at the highest dose in the SURPASS diabetes program
72 wks
Pivotal SURMOUNT-1 trial duration showing sustained weight loss vs. placebo
How it works
Regulates appetite and gastric emptying
Tirzepatide is a dual agonist: it activates both GLP-1 and GIP receptors. GLP-1 helps you feel full, slows stomach emptying, and supports insulin release. GIP adds a second metabolic signal that improves how the body handles fat and sugar. Together they create a more complete appetite and metabolic effect than GLP-1 alone.
- 1
Activates GLP-1 receptors
Reduces appetite, slows gastric emptying, and supports glucose-responsive insulin release.
- 2
Activates GIP receptors
Adds a complementary metabolic signal that improves how the body uses glucose and lipids.
- 3
Quiets food noise
Many patients describe fewer intrusive cravings and a calmer relationship with food.
Eligibility
Who tirzepatide is for
Generally a good fit for
- Adults with a BMI of 30 or higher, or 27+ with a weight-related health condition
- Patients who want a dual-pathway option for greater average weight loss
- Adults with type 2 diabetes seeking better glycemic control
- People who have not tolerated or fully responded to single-agonist GLP-1 therapy
Not appropriate for
- Pregnancy, planning pregnancy, or breastfeeding
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis or severe gastrointestinal disease such as gastroparesis
- Known hypersensitivity to tirzepatide or its components
Calculate your BMI
A starting point your provider considers alongside your full health profile.
BMI is a screening tool, not a diagnosis. Your provider will review your full health profile during the intake to determine eligibility.
Your BMI
—
Journey
What to expect & when
Weeks 1–4
- Noticeably smaller appetite and earlier fullness
- Possible mild nausea, reflux, or constipation as your body adjusts
- Some early weight change for many patients
Weeks 5–12
- Cravings continue to quiet as the dose climbs
- Steady weight loss for most patients
- Side effects often ease between titration steps
Months 3+
- Many patients continue losing through 9–12 months
- Improvements in energy, lipids, and A1C are common
- Maintenance dose is personalized as goals are reached
Ongoing
- Continued monitoring, dose adjustments, and cycling decisions guided by your PreventiveMD provider
Side effects
Safety & side effects
Tirzepatide's side-effect profile is similar to other GLP-1-based therapies, with gastrointestinal effects most common. Pacing titration is the single biggest lever for tolerability.
Common
- Nausea, especially early or after dose increases
- Diarrhea or constipation
- Bloating, reflux, or burping
- Decreased appetite (expected, sometimes intense)
- Injection-site reactions
Less common but serious
- Pancreatitis — severe, persistent abdominal pain
- Gallbladder disease, including gallstones
- Kidney injury from dehydration
- Possible thyroid C-cell tumors (seen in rodent studies; human risk unknown)
If you have questions about whether tirzepatide is right for you, your PreventiveMD provider will review your full health history once you get started.
Dosing
How to take tirzepatide
Typically titrated from 2.5 mg weekly to a maintenance dose of 5, 7.5, 10, 12.5, or 15 mg weekly, with increases every four weeks as tolerated. Specific dose is set by your provider based on goals and tolerance.
How to inject
- 1Wash your hands thoroughly.
- 2Choose an injection site your provider recommended, rotating to a different spot than your last injection.
- 3Clean the site with an alcohol wipe and let it dry completely, then inject as instructed.
- 4Place the used needle and syringe in your sharps container.
Seek emergency care immediately if you experience difficulty breathing or swallowing, swelling of the face, lips, tongue, or throat, hives or a widespread rash, dizziness or fainting, or a rapid heartbeat. These can be signs of a serious allergic reaction.
Pricing
Transparent pricing, no surprises
Loading pricing…
FAQs
In case you were wondering
Both reduce appetite and improve blood sugar. Tirzepatide adds a second receptor (GIP) on top of GLP-1, which in head-to-head studies has produced larger average weight loss. The right choice depends on your goals, history, and how you respond.
Most patients notice appetite changes within the first two weeks. Visible weight loss usually begins by week 4–8 and continues through month 9–12. Pace varies by person.
Yes. Baseline labs help your provider confirm tirzepatide is safe for you and give a starting point to track over time.
If fewer than 4 days have passed, take it as soon as you remember. If more, skip it and resume your normal schedule. Never double up.
Obesity is a chronic condition, so many patients stay on a maintenance dose long-term. Others step down once they've built habits that sustain their goal weight. We tailor that plan with you.
Our content is reviewed by our medical team and draws from peer-reviewed clinical research, FDA prescribing information, and recognized clinical guidelines. The primary sources cited on this page:
- [TODO: Pivotal clinical trial citation for tirzepatide]
[TODO: Authors, journal, year (DOI when available)]
- [TODO: Mechanism of action / review article]
[TODO: Authors, journal, year (DOI when available)]
- [TODO: FDA prescribing information / regulatory source]
- [TODO: Clinical society guideline or consensus statement]
How to get started
Preventive care begins here
Hi, I’m Eve, your care concierge. Ready to start when you are.
Currently, we are not yet available in Alaska, Kentucky, Louisiana, Mississippi, New Jersey, New Mexico, Rhode Island, and West Virginia. Get notified once we are.
Complete a 5-minute questionnaire
Choose your protocols
Self-pay checkout
Your provider prescribes if it’s the right fit
By starting, you agree to our Terms of Use and acknowledge our Privacy Policy.
